Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
出版年份 2015 全文链接
标题
Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 15, Issue 1, Pages 43-52
出版商
Informa Healthcare
发表日期
2015-11-11
DOI
10.1517/14740338.2016.1112375
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety and Tolerability of Infliximab Therapy: Suggestions and Criticisms Based on Wide Clinical Experience
- (2017) A. Vultaggio et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Anti-TNF-α Inhibitors: A New Therapeutic Approach for Inflammatory Immune-Mediated Diseases: An Update upon Efficacy and Adverse Events
- (2017) G. Murdaca et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Infection risk associated with anti-TNF-α agents: a review
- (2015) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis
- (2015) Meghna Jani et al. LANCET
- Pharmacogenetics and Future Therapeutic Scenarios: What Affects the Prediction of Response to Treatment with Etanercept?
- (2014) Giuseppe Murdaca et al. DRUG DEVELOPMENT RESEARCH
- Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy
- (2014) Giuseppe Murdaca et al. Expert Opinion on Drug Metabolism & Toxicology
- Efficacy and safety of etanercept in chronic immune-mediated disease
- (2014) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety
- (2014) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- Potential use of TNF-α inhibitors in systemic sclerosis
- (2014) Giuseppe Murdaca et al. Immunotherapy
- TNF-α Gene Polymorphisms: Association with Disease Susceptibility and Response to Anti-TNF-α Treatment in Psoriatic Arthritis
- (2014) Giuseppe Murdaca et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
- (2014) Éva Pallagi-Kunstár WORLD JOURNAL OF GASTROENTEROLOGY
- Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors
- (2013) A. C. Moss et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
- (2013) Eva L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- Defective CD8+CD28−regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy
- (2013) S. Ceeraz et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis
- (2013) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- Selective TNF-α inhibitor-induced injection site reactions
- (2013) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- Effects of TNF-α inhibitors upon the mechanisms of action of VEGF
- (2013) Giuseppe Murdaca et al. Immunotherapy
- Free radicals and endothelial dysfunction: Potential positive effects of TNF-α inhibitors
- (2013) Giuseppe Murdaca et al. REDOX REPORT
- The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
- (2013) M. Jani et al. RHEUMATOLOGY
- Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab
- (2012) Chamaida Plasencia et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
- (2012) Charlotte L Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
- (2012) Pauline A van Schouwenburg et al. ANNALS OF THE RHEUMATIC DISEASES
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
- (2012) Sandra Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity to Biologics: Mechanisms, Prediction and Reduction
- (2012) Swaminathan Sethu et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Endothelial dysfunction in rheumatic autoimmune diseases
- (2012) Giuseppe Murdaca et al. ATHEROSCLEROSIS
- Different effects of biological drugs in rheumatoid arthritis
- (2012) Fabiola Atzeni et al. AUTOIMMUNITY REVIEWS
- Delayed Hypersensitivity Reaction with Infliximab: Unusual to Occur After Initial Dose
- (2012) Mazer R. Ally et al. INFLAMMATORY BOWEL DISEASES
- Determination of Lymphotoxin-Alpha Levels in Patients with Psoriatic Arthritis Undergoing Etanercept Treatment
- (2012) Giuseppe Murdaca et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Adalimumab for the treatment of Behcet's disease: experience in 19 patients
- (2012) D. Perra et al. RHEUMATOLOGY
- The Effect of Tumor Necrosis Factor-α Antagonists on Arterial Stiffness in Rheumatoid Arthritis: A Literature Review
- (2012) Rajdip Dulai et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
- (2011) C. Steenholdt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab desensitization after anaphylactic reaction
- (2011) Oliviero Quercia et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events
- (2011) Giuseppe Murdaca et al. AUTOIMMUNITY REVIEWS
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
- (2011) Adedigbo A. Fasanmade et al. CLINICAL THERAPEUTICS
- Update upon efficacy and safety of TNF-α inhibitors
- (2011) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases
- (2011) Giuseppe Murdaca et al. Internal and Emergency Medicine
- Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
- (2011) A.A. Fasanmade et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease
- (2011) Casper Steenholdt et al. Journal of Crohns & Colitis
- Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis
- (2011) ROBERT LAUNOIS et al. JOURNAL OF RHEUMATOLOGY
- Anti-Tumor Necrosis Factor-α Treatment with Infliximab for Disseminated Granuloma Annulare
- (2010) Giuseppe Murdaca et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis
- (2010) A. W. R. van Kuijk et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy
- (2010) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab
- (2010) Miha Kosmač et al. PEDIATRIC RESEARCH
- Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
- (2009) A. Vultaggio et al. ALLERGY
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- 236-P: The HLA DRβ13 residue is associated with the development of human anti-chimeric antibody in some Crohn's patients treated with infliximab
- (2009) E. Magira et al. HUMAN IMMUNOLOGY
- Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease
- (2009) Andrea Cassinotti et al. INFLAMMATORY BOWEL DISEASES
- Targeted depletion of lymphotoxin-α–expressing TH1 and TH17 cells inhibits autoimmune disease
- (2009) Eugene Y Chiang et al. NATURE MEDICINE
- Vascular effects of biologic agents in RA and spondyloarthropathies
- (2009) Zoltán Szekanecz et al. Nature Reviews Rheumatology
- Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
- (2009) Klaus Bendtzen et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Serum vascular endothelial growth factor and sublingual immunotherapy
- (2008) G. Ciprandi et al. ALLERGY
- Traditional and non traditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: Role of vascular endothelial growth factor (VEGATS Study)
- (2008) Barbara Maria Colombo et al. AUTOIMMUNITY REVIEWS
- Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus
- (2008) Giorgio Ciprandi et al. HUMAN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started